-
cholorpromazine
- 1st gen, antipsychotic
- MOA: D2, H1, M1, alpha 2 antagonist (BLOCKS EVERYTHING)
- USES: typical or conventional antipsychotic - decreases + symptoms but doesn't help with - symptoms, antiemetic
- AE: sedation, weight gain, akathesia, rare (neuroleptic malignant syndrome), tardive dyskinesia (use antimuscarinics to manage)
-
haloperidol
- 1st gen, antipsychotic
- MOA: D2 antagonist - very potent, alpha1 antagonist
- USES: schizophrenia,
- AE: very potenet to most likely to have dyskinesias, sedation, weight gain, NMS,
- CI in parkinson's disease, increases prolactin - causing gynecomastia, amenorrhea
-
clozapine
- atypical, antipsychotic
- MOA: 5HT1A partial agonist, 5HT2A antagonist, decreases + and - symptoms. 5HT inhibits DA release, if you inhibit 5HT you will get more DA release.
- USES: treatment-resistant schizophrenia, reduction in risk of recurrent suicidal behavior, used in high functioning schizophrenia,
- AE: sedation, highest risk for diabetes, agranulocytosis - blood counts must be measured
- no EPS liability, reduce tardive dyskinesias
-
olanzepine
- atypical antipsychotic
- MOA: 5HT2A antagonist, D2 antagonist
- USES: schizophrenia, bipolar maintenance, reduces + and - symptoms, inreases DA to reduce motor symptoms
- AE: sedation, weight gain, high risk for diabetes
-
quetiapine
- atypical antipsychotic
- MOA: 5HT1A partial agonist, 5HT2A antagonist, DA receptor antagonist
- USES: preferred in psychosis in PD and lewy body disease, acute and maintenance schizophrenia
- AE: sedation, dry mouth, constipation
- has no motor side effects and no prolactin elevation
-
risperidone
- atypical antipsychotic
- MOA: 5HT2A antagonist, D2 antagonist, doesn't bind muscarinic or histamine receptors, still binds to alpha receptors
- USES: schizophrenia, acute maintenance, approved for 13-17
- AE: high doess can produce ESPs, weight gain
-
asenapine
- atypical antipsychotic
- MOA: 5HT2A antagonist, D2 antagoinst, binds H1 and alpha1
- USES: schziophrenia, acute tx ofr mania and mixed mania
- AE: high doses can produce ESP, weight gain
- sublingual tablet
-
aripiprazole
- atypical antipsychotic
- MOA: 5HT1A partial agonist, 5HT2A antagonist, D2 partial agonist
- USES: stabalizes DA, schizophrenia, acute and maintenance, approved to treat irritability in autism children 6-17
- AE: less sedation and weight gain, akathisia, low risk for diabetes
|
|